Literature DB >> 8545200

Screening for congenital adrenal hyperplasia: the Delfia Screening Test overestimates serum 17-hydroxyprogesterone in preterm infants.

S al Saedi1, H Dean, W Dent, E Stockl, C Cronin.   

Abstract

OBJECTIVE: To compare 17-hydroxyprogesterone (17-OHP) levels measured by quantitative serum radioimmunoassay (RIA), including an extraction step, and by screening fluoroimmunoassay (FIA) on blood spots in preterm infants.
METHODS: Subjects were 39 healthy infants born at less than 31 weeks' gestational age. Each infant had weekly blood sampling, and RIA and FIA were performed on each sample.
RESULTS: Two hundred twenty-seven samples were taken at 28 to 41 weeks' postconceptional age. Mean +/- SD 17-OHP measured by RIA was 11.4 +/- 11.1 nmol/L (0.4 +/- 0.4 micrograms/dL), and decreased over time. Mean +/- SD 17-OHP measured by FIA was 38.96 +/- 37.3 nmol/L, greater than 17-OHP (RIA). Log(delta FIA-RIA) was inversely related to postconceptional age (R2 = .39).
CONCLUSION: Screening FIA of blood spots overestimates levels of 17-OHP in preterm infants and should not be used to determine the likelihood of congenital adrenal hyperplasia in this population. We have abandoned FIA screening for congenital adrenal hyperplasia in infants weighing less than 1500 g.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8545200

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

1.  Longitudinal measurements of 17alpha-hydroxyprogesterone in premature infants during the first three months of life.

Authors:  N Linder; N Davidovitch; A Kogan; A Barzilai; J Kuint; R Mazkeret; J Sack
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-11       Impact factor: 5.747

Review 2.  Neonatal screening for congenital adrenal hyperplasia.

Authors:  Perrin C White
Journal:  Nat Rev Endocrinol       Date:  2009-09       Impact factor: 43.330

Review 3.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

4.  Analysis of a pitfall in congenital adrenal hyperplasia newborn screening: evidence of maternal use of corticoids detected on dried blood spot.

Authors:  Muriel Houang; Thao Nguyen-Khoa; Thibaut Eguether; Bettina Ribault; Séverine Brabant; Michel Polak; Irène Netchine; Antonin Lamazière
Journal:  Endocr Connect       Date:  2022-06-15       Impact factor: 3.221

Review 5.  Recent advances in biochemical and molecular analysis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Jin-Ho Choi; Gu-Hwan Kim; Han-Wook Yoo
Journal:  Ann Pediatr Endocrinol Metab       Date:  2016-03-31

6.  17-hydroxiprogesterone values in healthy preterm infants.

Authors:  Víctor Clemente Mendoza-Rojas; Luis Alfonso Díaz-Martínez; Gerardo Mantilla-Mora; Gustavo Adolfo Contreras-García; Víctor Manuel Mora-Bautista; Jhon Freddy Martínez-Paredes; Alba Luz Calderón-Rojas; Carlos Augusto Gómez-Tarazona; Katherine Pinzón-Mantilla
Journal:  Colomb Med (Cali)       Date:  2017-12-30

7.  Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based study.

Authors:  Atsumi Tsuji; Kaoru Konishi; Satomi Hasegawa; Akira Anazawa; Toshikazu Onishi; Makoto Ono; Tomohiro Morio; Teruo Kitagawa; Kenichi Kashimada
Journal:  BMC Pediatr       Date:  2015-12-15       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.